ATS President’s Message: The ATS Gets a Makeover!
Today we unveil our new logo, the most visible manifestation of our Society’s comprehensive rebranding effort.
Why rebrand? Why now? What does this mean for our members?
ATS has always evolved as an organization. We started as the American Sanitorium Society in 1905, in response to the tuberculosis epidemic. Our name has changed several times over the past century, and our focus has expanded to include pulmonary, critical care and sleep medicine—in the Americas and around the world.
Now, we’ve updated our mission to reflect that broader focus:
To accelerate global innovation in the advancement of respiratory health through multidisciplinary collaboration, education, and advocacy.
I think you’ll agree that this revised mission is particularly relevant in light of the COVID-19 global pandemic.
We also reorganized our brand pillars to better reflect our Society’s primary activities in a way that emphasizes the collaborations, rather than the differences, between specialists in respiratory disease.
Click here to continue to the full message from ATS President Lynn Schnapp, MD, ATSF!
Submit Your Abstracts or Case Reports for ATS 2022!
Join us for the ATS 2022 International Conference in San Francisco! Abstracts can report on basic, translational, and clinical science research; epidemiologic, social, biobehavioral, and psychosocial investigations; or educational and quality improvement projects.
If you would like guidance as you begin the submission process, please see our resources:
- Criteria, Word Count, and Submission Fee
- Instructions for Submitting an Abstract
- List of Scientific Abstract Classifications
- List of Case Report Classifications
View the full submission criteria, and begin yours today!
Deadline: 5 p.m. ET, Nov. 3, 2021
Apply Now! 2021 Research Grant Cycle
The ATS Research Program Grant Cycle is open!
Thanks to our partners, we are able to maximize the number of grants we can support. In addition to partner grants, the 2021 portfolio will include the ATS Unrestricted Grants, an ATS Diversity Grant, and the ATS Nursing Research Grant. Learn more and apply!
Upcoming Events
Today! Industry Innovations, “REPLACE: (Riociguat rEplacing PDE5i therapy evaLuated Against Continued PDE5i thErapy): A Look at Phase IV Study Data”
This virtual learning session will review the clinical data from a recent Phase IV study.
When: 6:30 p.m. Sept. 1, 2021
Register Now!
Sponsored by Bayer Healthcare
Industry Innovations, “The Role of Enhanced Pathogen Detection in the Management of Septic Pneumonia Patients”
When: 6:30 p.m. ET, Sept. 7, 2021
Register now!
Sponsored by BioFire Diagnostics, LLC
COVID-19 Critical Care Training Forum: COVID-19 Vaccine, Boosters, and the Future of COVID-19 Vaccination
When: 8 p.m. ET, Sept. 7, 2021
Register now!
Pulmonary Fibrosis and Hermansky-Pudlak Syndrome: Diagnosis, Treatment, and Management of Your Lung Fibrosis
Please join us for a virtual roundtable hosted by the American Thoracic Society Public Advisory Roundtable in partnership with the Hermansky-Pudlak Syndrome Network, as part of its “Lung Disease Week at the ATS” initiative, a program designed to facilitate information exchange between patients and experts on matters relating to lung and airway disorders.
When: 3 p.m. ET, Sept. 9, 2021
Register now!
CME Opportunity! EGPA: Facilitating Prompt Recognition and Optimal Treatment
This one-hour activity led by three EGPA experts will address the most current information on the diagnosis, treatment initiation, and long-term monitoring of this rare eosinophilic disorder. Full CME information is available here.
Expires: Nov. 13, 2021
Register and get started now!
Supported by an educational grant from GlaxoSmithKline.
PINE Series: Cystic Fibrosis
Join the ATS Assembly on Pulmonary Infections (PI-TB) Early Career Professionals Working Group, for a “Pulmonary Infection Network of Experts” (PINE) webinar. PINE seeks to highlight a different pulmonary infection each month.
When: 3 p.m. ET, Sept. 10, 2021
Register now!
Potential Overuse of Antibiotics Found in Patients with Severe COVID-19 Pneumonia
Only 21 percent of patients with severe pneumonia caused by SARS-CoV-2 (the virus that causes COVID-19) have a documented bacterial superinfection at the time of intubation, resulting in potential overuse of antibiotics, according to new research published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine. Superinfection takes place when another, often different, infection is superimposed on the initial infection; in this case, bacterial pneumonia occurring during severe viral pneumonia.
